Hepagene Therapeutics Receives FDA Clearance for HPG7233 THR Beta Agonist IND Application

Hepagene Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for HPG7233, a Thyroid Hormone Receptor beta (THR-β) agonist designed to address the pressing needs of patients suffering from non-alcoholic steatohepatitis (NASH) and dyslipidemia.

HPG7233 represents a remarkable advancement in therapeutic innovation. It stands out as a liver-targeted, highly selective small molecule thyroid hormone receptor beta (THR-β) agonist that targets serum and liver lipid metabolism with exceptional precision. 

Furthermore, HPG7233 has demonstrated excellent selectivity for target tissues, offering an added layer of safety and specificity. Toxicology studies have provided results, with no adverse findings related to THR-α subtypes or gastrointestinal tract issues, confirming its suitability for clinical development.

The preclinical studies have demonstrated its exceptional selectivity, potency, and its ability to greatly enrich the liver while maintaining an optimal liver/plasma exposure profile in both rodent and non-rodent animal models. Moreover, HPG7233 has consistently shown its ability to significantly reduce liver triglyceride levels, lower serum LDL-C (Low-Density Lipoprotein Cholesterol), and effectively reduce the NAS (NAFLD Activity Score) in NASH animal models.

Based on its preclinical profile, HPG7233 holds the promise of becoming the next generation THR-β agonist, offering new hope and potential for patients grappling with NASH and dyslipidemia.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!